These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 31062609)

  • 21. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
    Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
    J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular Dystrophy.
    Happi Mbakam C; Rousseau J; Tremblay G; Yameogo P; Tremblay JP
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy.
    Lim KRQ; Nguyen Q; Dzierlega K; Huang Y; Yokota T
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32213923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From gRNA Identification to the Restoration of Dystrophin Expression: A Dystrophin Gene Correction Strategy for Duchenne Muscular Dystrophy Mutations Using the CRISPR-Induced Deletion Method.
    Duchêne B; Iyombe-Engembe JP; Rousseau J; Tremblay JP; Ouellet DL
    Methods Mol Biol; 2018; 1687():267-283. PubMed ID: 29067670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy.
    Moretti A; Fonteyne L; Giesert F; Hoppmann P; Meier AB; Bozoglu T; Baehr A; Schneider CM; Sinnecker D; Klett K; Fröhlich T; Rahman FA; Haufe T; Sun S; Jurisch V; Kessler B; Hinkel R; Dirschinger R; Martens E; Jilek C; Graf A; Krebs S; Santamaria G; Kurome M; Zakhartchenko V; Campbell B; Voelse K; Wolf A; Ziegler T; Reichert S; Lee S; Flenkenthaler F; Dorn T; Jeremias I; Blum H; Dendorfer A; Schnieke A; Krause S; Walter MC; Klymiuk N; Laugwitz KL; Wolf E; Wurst W; Kupatt C
    Nat Med; 2020 Feb; 26(2):207-214. PubMed ID: 31988462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
    Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9.
    Koo T; Lu-Nguyen NB; Malerba A; Kim E; Kim D; Cappellari O; Cho HY; Dickson G; Popplewell L; Kim JS
    Mol Ther; 2018 Jun; 26(6):1529-1538. PubMed ID: 29730196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
    Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
    Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.
    Nelson CE; Hakim CH; Ousterout DG; Thakore PI; Moreb EA; Castellanos Rivera RM; Madhavan S; Pan X; Ran FA; Yan WX; Asokan A; Zhang F; Duan D; Gersbach CA
    Science; 2016 Jan; 351(6271):403-7. PubMed ID: 26721684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correction of exon 2, exon 2-9 and exons 8-9 duplications in DMD patient myogenic cells by a single CRISPR/Cas9 system.
    Lemoine J; Dubois A; Dorval A; Jaber A; Warthi G; Mamchaoui K; Wang T; Corre G; Bovolenta M; Richard I
    Sci Rep; 2024 Sep; 14(1):21238. PubMed ID: 39261505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.
    Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD
    Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
    Zhang Y; Bassel-Duby R; Olson EN
    Methods Mol Biol; 2023; 2587():411-425. PubMed ID: 36401041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.
    Ousterout DG; Kabadi AM; Thakore PI; Majoros WH; Reddy TE; Gersbach CA
    Nat Commun; 2015 Feb; 6():6244. PubMed ID: 25692716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
    Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
    Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
    Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo.
    Duchêne BL; Cherif K; Iyombe-Engembe JP; Guyon A; Rousseau J; Ouellet DL; Barbeau X; Lague P; Tremblay JP
    Mol Ther; 2018 Nov; 26(11):2604-2616. PubMed ID: 30195724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR-Editing Therapy for Duchenne Muscular Dystrophy.
    Chemello F; Olson EN; Bassel-Duby R
    Hum Gene Ther; 2023 May; 34(9-10):379-387. PubMed ID: 37060194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA.
    Long C; McAnally JR; Shelton JM; Mireault AA; Bassel-Duby R; Olson EN
    Science; 2014 Sep; 345(6201):1184-1188. PubMed ID: 25123483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common therapeutic advances for Duchenne muscular dystrophy (DMD).
    Salmaninejad A; Jafari Abarghan Y; Bozorg Qomi S; Bayat H; Yousefi M; Azhdari S; Talebi S; Mojarrad M
    Int J Neurosci; 2021 Apr; 131(4):370-389. PubMed ID: 32241218
    [No Abstract]   [Full Text] [Related]  

  • 40. Age-Dependent Echocardiographic and Pathologic Findings in a Rat Model with Duchenne Muscular Dystrophy Generated by CRISPR/Cas9 Genome Editing.
    Sugihara H; Kimura K; Yamanouchi K; Teramoto N; Okano T; Daimon M; Morita H; Takenaka K; Shiga T; Tanihata J; Aoki Y; Inoue-Nagamura T; Yotsuyanagi H; Komuro I
    Int Heart J; 2020 Nov; 61(6):1279-1284. PubMed ID: 33191355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.